Generation and characterization of mesenchymal stromal cells for clinical application

被引:1
|
作者
Sensebe, L. [1 ]
机构
[1] EFS Ctr Atlantique, Dept Res, Tours 3, France
关键词
clinical trials; controls; GMP; Mesenchymal Stem Cells; HUMAN BONE-MARROW; UMBILICAL-CORD BLOOD; ADULT STEM-CELLS; HUMAN ADIPOSE-TISSUE; EX-VIVO EXPANSION; IN-VITRO; PROGENITOR CELLS; OSTEOGENESIS IMPERFECTA; T-CELLS; GROWTH;
D O I
10.1111/j.1751-2824.2009.01225.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mesenchymal Stem Cells/Multipotent Marrow Stromal Cells (MSC) are multipotent adult stem cells harboring a wide range of differentiation capacities as well as non-HLA restricted immunosuppressive properties, leading to an increase in their uses for immunomodulation and regenerative medicine. MSC are generally cultivated from bone marrow (BM). Alternative sources (e.g. adipose tissue or umbilical cord) are rapidly developing. Considering the starting material used, the differentiation potential may be different, in example adipose tissue derived MSC exhibit a greater potential for endothelium repair. Whatever the sources of MSC, a first step of adherence to plastic is required. When seeding, the cell density is of major importance acting on growth speed, cell amplification, and differentiation potential. Considering medium used, until now serum free media are not available to cultivate MSC for clinical application. Standard process with FCS without any growth factor supplementation is effective but time consuming, sometime failing, and not totally secure. Although processes using recombinant growth factors (e.g. FGF2) or platelet lysate have demonstrated their interest, definitive standards to produce clinical-grade MSC are still lacking. To reach GMP standards, two major steps have to be done. First, MSC cultures need to be done in closed system; this step is not easy to perform. Second, the controls of produced batches have to ensure efficacy and safety. Now, the controls are principally based on FACS analysis and the expected CD731(pos)CD105(pos)CD90(pos)CD45(neg) MSC phenotype is easily obtained. But the major problem remains the lack of fully validated controls of the final cell product efficacy and safety. Considering the genetic stability of MSC during culture processes, whatever the culture method, aneuploidy could occur during clinical-grade production of BM-MSC but does not lead to cell transformation. But these results should lead to develop more accurate and powerful controls of all MSC in cultures.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 50 条
  • [21] Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application
    Sessarego, Nadia
    Parodi, Alessia
    Podesta, Marina
    Benvenuto, Federica
    Mogni, Massimo
    Raviolo, Valentina
    Lituania, Mario
    Kunkl, Annalisa
    Ferlazzo, Guido
    Bricarelli, Franca Dagna
    Uccelli, Antonio
    Frassoni, Francesco
    [J]. HAEMATOLOGICA, 2008, 93 (03) : 339 - 346
  • [22] Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical Application
    Bozorgmehr, Mahmood
    Gurung, Shanti
    Darzi, Saeedeh
    Nikoo, Shohreh
    Kazemnejad, Somaieh
    Zarnani, Amir-Hassan
    Gargett, Caroline E.
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [23] Generation and Characterization of an Immortalized Human Mesenchymal Stromal Cell Line
    Skarn, Magne
    Noordhuis, Paul
    Wang, Meng-Yu
    Veuger, Marjan
    Kresse, Stine Henrichson
    Egeland, Eivind Valen
    Micci, Francesca
    Namlos, Heidi Maria
    Hakelien, Anne-Mari
    Olafsrud, Solveig Mjelstad
    Lorenz, Susanne
    Haraldsen, Guttorm
    Kvalheim, Gunnar
    Meza-Zepeda, Leonardo Andres
    Myklebost, Ola
    [J]. STEM CELLS AND DEVELOPMENT, 2014, 23 (19) : 2377 - 2389
  • [24] Characterization of mesenchymal stromal cells: potency assay development
    Hematti, Peiman
    [J]. TRANSFUSION, 2016, 56 (04) : 32S - 35S
  • [25] Characterization of Induction and Targeting of Senescent Mesenchymal Stromal Cells
    Gresham, Robert C. H.
    Kumar, Devanshi
    Copp, Jonathan
    Lee, Mark A.
    Leach, J. Kent
    [J]. TISSUE ENGINEERING PART C-METHODS, 2022, 28 (06) : 239 - 249
  • [26] Isolation and characterization of equine endometrial mesenchymal stromal cells
    B. Elisabeth Rink
    Karin R. Amilon
    Cristina L. Esteves
    Hilari M. French
    Elaine Watson
    Christine Aurich
    F. Xavier Donadeu
    [J]. Stem Cell Research & Therapy, 8
  • [27] Isolation and characterization of equine endometrial mesenchymal stromal cells
    Rink, B. Elisabeth
    Amilon, Karin R.
    Esteves, Cristina L.
    French, Hilari M.
    Watson, Elaine
    Aurich, Christine
    Donadeu, F. Xavier
    [J]. STEM CELL RESEARCH & THERAPY, 2017, 8
  • [28] CHARACTERIZATION OF INTERACTIONS BETWEEN MONOCYTES AND MESENCHYMAL STROMAL CELLS
    Kienzle, T.
    Zambarda, C.
    Nasi, A.
    Onfelt, B.
    Kadri, N.
    [J]. CYTOTHERAPY, 2023, 25 (06) : S63 - S63
  • [29] In Vitro Characterization of Patches of Human Mesenchymal Stromal Cells
    Roux, Stephan
    Bodivit, Gwellaouen
    Bartis, Widy
    Lebouvier, Angelique
    Chevallier, Nathalie
    Fialaire-Legendre, Anne
    Bierling, Philippe
    Rouard, Helene
    [J]. TISSUE ENGINEERING PART A, 2015, 21 (3-4) : 417 - 425
  • [30] Therapeutic application of mesenchymal stromal cells in autoimmune disease
    Keysser, G.
    Mueller, L.
    Schendel, M.
    Schmoll, H. -J.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2009, 68 (03): : 220 - +